Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular ...(ons are estimated to be the fifth-leadin...)

Date:11/9/2007

ons are estimated to be the fifth-leading cause of death in the U.S., after heart disease, cancer, stroke, and pneumonia or influenza. The CDC estimates that nearly two million Americans a year acquire healthcare-associated infections. There are several types of healthcare-associated infections -- of these, blood stream infections are the most costly and life-threatening, resulting in an increase in mortality rate of 18 percent when compared to patients without a blood stream infection. Leading researchers have estimated that more than 400,000 blood stream infections occur each year in the U.S. alone. Healthcare-acquired blood stream infections cost an average of $34,000 in increased direct hospital costs and can increase patient length-of-stays by 23 days. Many hospitals and other healthcare facilities have developed extensive control programs to prevent the occurrence of infections. Even when clinicians in hospitals do their best to practice good hygiene techniques, the risk of pathogen contamination may still persist.

About Medication Delivery

For more than 75 years, Baxter has pioneered products designed to help reduce errors throughout the medication management process by improving the interface between technology and clinicians. For example, to help prevent accidental needle-stick injuries, Baxter introduced the industry's first "needleless" IV access system. Baxter also set a new industry standard with the introduction of its bar code technology, the first bar code for flexible, plastic IV containers that incorporates lot number and expiration date. In the coming year, Baxter plans to introduce a new integrated portfolio of infusion pumps and administration sets, designed to promote increased security and confidence in delivery of IV medications.

About Baxter

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE:

SOURCE Baxter Healthcare Corporation Copyright©2007 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4
Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. IsoTis Receives FDA Clearance for Accell Family of Products